Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by α1 nicotinic acetylcholine receptor-mediated activation in PC9 cells

Journal of Thoracic Oncology

Volumn 8, Issue 6, 2013, Pages 719-725

  Wang, Shuo ^a   Takayama, Koichi ^a   Tanaka, Kentaro ^a   Takeshita, Masafumi ^a   Nakagaki, Noriaki ^a   Ijichi, Kayo ^a   Li, Heyan ^a   Nakanishi, Yoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Epidermal growth factor receptor tyrosine kinase inhibitor; Nicotine; Nicotinic acetylcholine receptors; Non small cell lung cancer; Targeting therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINE; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA1; NICOTINIC RECEPTOR; PROTEIN KINASE B; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84879506069     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31828b51d4     Document Type: Article

References (36)

1. Dasgupta P, Rizwani W, Pillai S, et al. Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer 2009;124:36-45.
2. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001;61:3986-3997. (Pubitemid 32720961)
3. Dasgupta P, Kinkade R, Joshi B, et al. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A 2006;103:6332-6337.
4. Herbst RS, Heymach JV, Lippman SM. Molecular origins of cancer: lung cancer. N Engl J Med 2008;359:1367-1380.
5. Catassi A, Servent D, Paleari L, et al. Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: implications on lung carcinogenesis. Mutat Res-Rev Mutat Res 2008;659:221-231.
6. Heeschen C, Jang JJ, Weis M, et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001;7:833-839. (Pubitemid 32691639)
7. Dasgupta P, Rastogi S, Pillai S, et al. Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 2006;116: 2208-2217. (Pubitemid 44162330)
8. Heeschen C, Weis M, Aicher A, et al. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Invest 2002;110:527-536. (Pubitemid 34919707)
9. Dasgupta P, Chellappan SP. Nicotine-mediated cell proliferation and angiogenesis: new twists to an old story. Cell Cycle 2006;5:2324-2328. (Pubitemid 44801377)
10. Carlisle DL, Liu X, Hopkins TM, et al. Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells. Pulm Pharmacol Ther 2007;20:629-641. (Pubitemid 47446337)
11. Arias HR, Richards VE, Nga D, et al. Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis. Int J Biochem Cell Biol 2009;41:1441-1451.
12. Wu CH, Lee CH, Ho YS. Nicotinic acetylcholine receptor-based blockade: applications of molecular targets for cancer therapy. Clin Cancer Res 2011;17:3533-3541.
13. Egleton RD, Brown KC, Dasgupta P. Nicotinic acetylcholine receptors in cancer: multiple roles in proliferation and inhibition of apoptosis. Trends Pharmacol Sci 2008;29:151-158.
14. Dasgupta P, Rastogi S, Pillai S, et al. Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 2006;116:2208-2217. (Pubitemid 44162330)
15. Carlisle DL, Hopkins TM, Gaither-Davis A, et al. Nicotine signals through muscle-type and neuronal nicotinic acetylcholine receptors in both human bronchial epithelial cells and airway fibroblasts. Respir Res 2004;5:27.
16. Zhang JM, Kamdar O, Le W, et al. Nicotine induces resistance to chemotherapy by modulating mitochondrial signaling in lung cancer. Am J Respir Cell Mol Biol 2009;40:135-146.
17. Shen TJ, Le W, Yee A, et al. Nicotine induces resistance to chemotherapy in nasal epithelial cancer. Am J Rhinol & Aller 2010;24:E73-E77.
18. Léna C, Changeux JP. Allosteric nicotinic receptors, human pathologies. J Physiol Paris 1998;92:63-74. (Pubitemid 29096219)
19. Lam DC, Girard L, Ramirez R, et al. Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res 2007;67:4638-4647. (Pubitemid 46910168)
20. Paleari L, Catassi A, Ciarlo M, et al. Role of alpha7-nicot/inic acetylcholine receptor in human non-small cell lung cancer proliferation. Cell Prolif 2009;42: 936-959.
21. Schuller HM. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat Rev Cancer 2009;9:195-205.
22. Katakami N, Sugiura T, Nogami T, et al. Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908. Lung Cancer 2004;43:93-100. (Pubitemid 38096298)
23. Ciardiello F, Tortora G. Drug therapy: EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-1174.
24. Heist RS, Christiani D. EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics 2009;10:59-68.
25. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced nonsmall- cell lung cancer. J Clin Oncol 2004;22:1103-1109. (Pubitemid 41095044)
26. Nakayama H, Numakawa T, Ikeuchi T. Nicotine-induced phosphorylation of Akt through epidermal growth factor receptor and Src in PC12h cells. Journal of Neurochemistry 2002;83:1372-1379. (Pubitemid 35477476)
27. Wang SL, Feng J, Correa A, et al. Effects of in vivo treatments of nicotine and benzo alpha pyrene on the epidermal growth factor receptor in hamster buccal pouch. Toxicology 1996;107:31-38. (Pubitemid 26061045)
28. Takata S, Takigawa N, Segawa Y, et al. STAT3 expression in activating EGFR-driven adenocarcinoma of the lung. Lung Cancer 2012;75:24-29.
29. Johnson BE. Tobacco and lung cancer. Prim Care 1998;25:279-+.
30. Zhu BQ, Heeschen C, Sievers RE, et al. Second hand smoke stimulates tumor angiogenesis and growth. Cancer Cell 2003;4:191-196. (Pubitemid 37163833)
31. Ye YN, Liu ESL, Shin VY, et al. Nicotine promoted colon cancer growth via epidermal growth factor receptor, c-Src, and 5-lipoxygenase-mediated signal pathway. J Pharmacol Exp Ther 2004;308:66-72. (Pubitemid 38090701)
32. Custodio A, Méndez M, Provencio M. Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. Cancer Treat Rev 2012;38:36-53.
33. Plummer HK 3rd, Dhar M, Schuller HM. Expression of the alpha7 nicotinic acetylcholine receptor in human lung cells. Respir Res 2005;6:29.
34. Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006;1:847-855. (Pubitemid 47181391)
35. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311. (Pubitemid 39209661)
36. Hamilton M, Wolf JL, Rusk J, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006;12(7 Pt 1):2166-2171.